DENALI LOGO FOR PRESS RELEASE.jpg
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
February 27, 2020 16:30 ET | Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
DENALI LOGO FOR PRESS RELEASE.jpg
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
December 10, 2018 09:00 ET | Denali Therapeutics Inc.
Phase 1b study includes Parkinson’s disease patients with and without a genetic LRRK2 mutation SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:...